Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

 Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Shots:

  • Thermo Fisher acquires a manufacturing facility in Ireland from GSK for ~$100M cash to develop & commercialize APIs for multiple diseases including childhood cancer, depression and Parkinson’s. The transaction is expected to close in H2’19 including regulatory approvals
  • The focus of the acquisition is to expand Thermo Fischer’s APIs manufacturing capabilities. Under a multi-year supply agreement, Thermo Fisher will continue to develop APIs for GSK
  • The manufacturing facility has 270m3 of reactor capacity, 10 production buildings, R&D pilot plant and a lab, supporting the development process, scale-up and physical characterization of APIs

Click here to read full press release/ article | Ref: Thermo Fischer | Image: Bellia.Net

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post